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University of Utrecht, Utrecht, Netherlands
Pneumococcal disease, including pneumonia, is a major global
public health problem, and older people are at greater risk, par-
ticularly for severe disease and complications. Conjugate vaccines
have shown efﬁcacy against invasive pneumococcal disease (IPD)
and otitis media in children, but have not been evaluated healthy
elderly. The CAPiTA study was designed was to demonstrate the
efﬁcacy of 13-valent pneumococcal conjugate vaccine (13vPnC)
in prevention of a ﬁrst episode of vaccine-type pneumococcal
community-acquired pneumonia (CAP) (primary objective). The
secondary objectives were to demonstrate efﬁcacy in preven-
tion of a ﬁrst episode of nonbacteremic/noninvasive vaccine-type
pneumococcal CAPandof vaccine-type invasive IPD. Thiswas a ran-
domized, double-blind clinical trial in 84,496 participants 65 and
older in the Netherlands. Key eligibility criteria were no previous
pneumococcal vaccination and immune competence. Participants
were randomized 1:1 to receive 13vPnC or placebo. They were
enrolled at community-based sites and home visits, and surveil-
lance for CAP and IPD was conducted at hospitals in the areas
of enrollment. A serotype-speciﬁc urinary antigen detection assay
was used to identify episodes of vaccine-type CAP. Safety was also
evaluated. The study started in September 2008, and reached the
protocol deﬁned 130 case accrual numbers of ﬁrst episode of Vac-
cineTypeCAPat theendofAugust2013. Theprimaryandsecondary
endpoints of this study will be presented. At the time abstract sub-
mission, the data were not yet available.
(Funded by Pﬁzer, Inc.; ClinicalTrials.govnumber
NCT00744263.)
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Infectious diseases in refugees coming from
Syria and Iraq to Lebanon
I. Beldjebel
St. Charles Foucauld Health Centre, St. Elisabeth
University, Beirut, Lebanon
During the last 3 years, roughly 600.000 Syrian refugees and
300.000 Iraqi refugees have been registered in Lebanon, and
400.000 and 250.000, respectively in Turkey as reported by United
Nations High Commissioner for Refugees (UNHCR). Here we report
spectrum of infectious diseases (IDs) observed among Iraqui and
Syrian refugees in SEU refugee camp. UNHCR camp in Beirut serves
for 2 generations of refugees since 1990 and St. Charles Foucauld
HealthCentre treats patients in this camp,with30-50 casesper day,
bothadults andchildren. In addition,mobile clinic operates to those
families living in Beirut suburbs or outside the camp, with average
of 8,5 visits daily. The prevalence of different non-communicable
and infectious diseases was assessed in St. Charles Foucauld Health
Centre from2000 - 2013. Altogether, 28.343patients, both refugees
and migrants, have been reported in 2009 - 2013. More than 92% of
them were Iraqi and Syrian asylum seekers. Among adults, hyper-
tension, diabetes and coronary and/or vascular cerebral disease
were predominant. IDs in adult represented only 28,5%,majority of
them were respiratory tract infections (RTI), followed by skin and
soft tissue infections (SSTI).Amongchildren, the situationwasmore
difﬁcult - up to 90% of all paediatric patients presented with ID.
Of these, 21,2% had gastrointestinal infections and 19,1% had SSTI
(streptococcal, scabies, lice and other). Sporadic cases of measles
were seen in 20012/2013. War conﬂicts in Middle East represent a
majorhealth issue inneighbouringcountries, especially inLebanon,
Jordan and Turkeywith respect to Syriawar. Infrastructure of these
countries is not prepared to serve for increasing number of IDs
patients despite the efforts of UNHCR and non-governmental insti-
tutions.
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Spectrum of infectious diseases among
internally displaced refugees in South Sudan
and north Kenya
M. Bartkovjak ∗, V. Krcmery
Mary Immaculate Clinic, St. Elisabeth University
(SEU) Tropical Program Yirol County, Mapuordit,
South Sudan
Within last 25 years (1980-2005) about 1.1 million people in
South Sudan has been either internally displaced (estimated 200
thousand)within different provinces in South Sudan or crossed the
border to Uganda (200 000) and Kenya (360 000) or Ethiopia (140
000) or Democratic Republic of Congo (DRC; 110 000 estimated).
The aim of this communication is to compare spectrum of infec-
tious diseases (IDs) among internally displaced Sudanese people
within Bahr el Ghazal in South versus to north Kenya. Spectrum
and outcomes of IDs in Mary Immaculate SEU Tropic Hospital in
Mapuordit, serving for about 12 000 internally displaced Sudanese
patients, were compared with refugees crossing borders to north
Kenya and being treated in United Nations High Commissioner for
Refugees (UNHCR) Hospital and Médecins Sans Frontières (MSF)
facilities in Kakuma, north Kenya (60-80 000 refugees). Most fre-
quent ID among admissions of internally displaced in Mapuordit
was malaria (9-48% admissions depending on season), followed by
meningitis (2-10%), neonatal sepsis (5-15%), severe diarrhoea (2-
5%), malnutrition (5-20%) with sepsis, leprosy (1-5%). Contrary, in
Kakuma (north Kenya) malaria was less common (5-30%) as well
as malnutrition (1-5%) complicated with diarrhoea, which is due
